Abstract
Background:
Severe forms of non-alcoholic fatty liver disease (NAFLD) adversely affect the liver physiology and hence the pharmacokinetics of drugs. Here, we investigated the effect of NAFLD on the pharmacokinetics of rosiglitazone, an insulin sensitizer used in the treatment of type 2 diabetes.
Methods:
Male C57BL/6 mice were divided into two groups. The first group (n=14) was fed with normal chow feed and the second group (n=14) was fed with 60% high-fat diet (HFD) and 40% high fructose liquid (HFL) for 60 days to induce NAFLD. The development of NAFLD was confirmed by histopathology, liver triglyceride levels and biochemical estimations, and used for pharmacokinetic investigations. Rosiglitazone was administered orally at 30 mg/kg dose. At predetermined time points, blood was collected and rosiglitazone concentrations were determined using LC/MS/MS. Plasma concentrations were subjected to non-compartmental analysis using Phoenix WinNonlin (6.3), and the area under the plasma concentration-time curve (AUC) was calculated by the linear-up log-down method.
Results:
HFD and HFL diet successfully induced NAFLD in mice. Rosiglitazone pharmacokinetics in NAFLD animals were altered significantly as compared to healthy mice. Rosiglitazone exposure increased significantly in NAFLD mice (2.5-fold higher AUC than healthy mice). The rosiglitazone oral clearance was significantly lower and the mean plasma half-life was significantly longer in NAFLD mice as compared to healthy mice.
Conclusions:
The NAFLD mouse model showed profound effects on rosiglitazone pharmacokinetics. The magnitude of change in rosiglitazone pharmacokinetics is similar to that observed in humans with moderate to severe liver disease. The present animal model can be utilized to study the NAFLD-induced changes in the pharmacokinetics of different drugs.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet 1999;37:399–43.10.2165/00003088-199937050-00004Search in Google Scholar PubMed
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434–8.Search in Google Scholar
3. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 2015;47:997–1006.10.1016/j.dld.2015.08.004Search in Google Scholar PubMed
4. Bertot LC, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 2016;17:774.10.3390/ijms17050774Search in Google Scholar PubMed PubMed Central
5. Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev 2011;43:317–34.10.3109/03602532.2011.577781Search in Google Scholar PubMed PubMed Central
6. Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabet Invest 2013;4:517–24.10.1111/jdi.12107Search in Google Scholar PubMed PubMed Central
7. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002;18:S10–5.10.1002/dmrr.249Search in Google Scholar PubMed
8. Chiarelli F, Marzio DD. Peroxisome proliferator-activated receptor-γ agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag 2008;4:297–304.10.2147/VHRM.S993Search in Google Scholar
9. Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22:18–23.10.1097/MEG.0b013e32832e2bafSearch in Google Scholar PubMed
10. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 2008;135:100–10.10.1053/j.gastro.2008.03.078Search in Google Scholar PubMed
11. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51:445–53.10.1002/hep.23270Search in Google Scholar PubMed
12. García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuán T, Martínez MA, Muñoz-Yagüe T, Solís-Herruzo JA. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology 2007;46:414–23.10.1002/hep.21687Search in Google Scholar
13. Zhou M, Xu A, Lam KS, Tam PK, Che CM, Chan L, et al. Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin. J Hepatol 2010;53:1108–16.10.1016/j.jhep.2010.05.034Search in Google Scholar
14. Mookkan J, De S, Shetty P, Kulkarni NM, Devisingh V, Jaji MS, et al. Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice. Indian J Pharmacol 2014;46:46–50.10.4103/0253-7613.125166Search in Google Scholar
15. Folch J, Lees M, Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497.10.1016/S0021-9258(18)64849-5Search in Google Scholar
16. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006;49:450–65.10.1111/j.1365-2559.2006.02416.xSearch in Google Scholar PubMed
17. Brunt EM, Tiniakos DG. Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:691–707.10.1053/bega.2002.0326Search in Google Scholar PubMed
18. Palatini P, Martin SD. Pharmacokinetic drug interactions in liver disease: an update. World J Gastroenterol 2016;22:1260–78.10.3748/wjg.v22.i3.1260Search in Google Scholar PubMed PubMed Central
19. Pirmohamed M. Prescribing in liver disease. Medicine 2015;43:577–80.10.1016/j.mpmed.2015.07.015Search in Google Scholar
20. Highlights of prescribing information. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM143394.pdf. Accessed 17 March, 2016.Search in Google Scholar
21. Atiken AE, Richardson TA, Morgan ET. Regulation of drug metabolic enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006;46:123–49.10.1146/annurev.pharmtox.46.120604.141059Search in Google Scholar PubMed
22. Hu D, Wu CQ, Li ZJ, Liu Y, Fan X, Wang QJ, et al. Characterizing the mechanism of thiazolidinedione- induced hepatotoxicity: an in vitro model in mitochondria. Toxicol Appl Pharmacol 2015;284:134–41.10.1016/j.taap.2015.02.018Search in Google Scholar PubMed
©2016 Walter de Gruyter GmbH, Berlin/Boston
